Stemirna Therapeutics, a Chinese biotech startup specialized in RNA technology-based drug development, has entered into a staged investment agreement with Shanghai-listed domestic pharma Tibet Rhodiola Pharmaceutical that could bring the startup capital injections of up to 351 million yuan ($50 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
